Corcept Therapeutics (CORT) Operating Income (2016 - 2025)
Historic Operating Income for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $10.2 million.
- Corcept Therapeutics' Operating Income fell 7806.99% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year decrease of 5426.03%. This contributed to the annual value of $137.0 million for FY2024, which is 2765.52% up from last year.
- Per Corcept Therapeutics' latest filing, its Operating Income stood at $10.2 million for Q3 2025, which was down 7806.99% from $26.7 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Operating Income ranged from a high of $46.6 million in Q3 2024 and a low of $3.4 million during Q1 2025
- In the last 5 years, Corcept Therapeutics' Operating Income had a median value of $29.6 million in 2023 and averaged $27.5 million.
- Per our database at Business Quant, Corcept Therapeutics' Operating Income soared by 9861.31% in 2024 and then tumbled by 8842.03% in 2025.
- Corcept Therapeutics' Operating Income (Quarter) stood at $36.7 million in 2021, then plummeted by 38.63% to $22.5 million in 2022, then surged by 40.76% to $31.7 million in 2023, then decreased by 20.23% to $25.3 million in 2024, then crashed by 59.55% to $10.2 million in 2025.
- Its last three reported values are $10.2 million in Q3 2025, $26.7 million for Q2 2025, and $3.4 million during Q1 2025.